



May 15,2023

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended March 31,2023

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (started at 6:50 p.m. and concluded at 8:00 p.m.), the Unaudited Financial Results for the quarter ended March 31, 2023 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2023;
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2023 furnished by Statutory Auditors of the Company

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

For Procter & Gamble Health Limited

Zeal Rupani
Company Secretary

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,
P&G Plaza, Cardinal Gracias Road, Chakala,
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000
www.pghealthindia.com

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

Highly Restricted

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 MARCH 2023

(₹ in lakhs)

Sr. No.	Particulars	(1)	(2)	(3)	(4)	(5)	(6)
		Three months ended 31st March 2023 (Unaudited)	Preceding Three months ended 31st December 2022 (Unaudited)	Corresponding Three months ended 31st March 2022 (Unaudited)	Nine Months ended 31st March 2023 (Unaudited)	Nine Months ended 31st March 2022 (Unaudited)	Year ended 30th June 2022 (Audited)
1.	Revenue from Operations	32,092.0	30,997.0	26,782.0	92,844.0	81,852.0	1,11,441.0
2.	Other Income	497.0	454.0	235.0	1,293.0	1,009.0	1,319.0
3.	Total income (1+2)	32,589.0	31,451.0	27,017.0	94,137.0	82,861.0	1,12,760.0
4.	Expenses						
	a) Cost of materials consumed	6,362.0	10,108.0	7,426.0	24,492.0	25,125.0	32,372.0
	b) Purchases of stock-in-trade	2,049.0	773.0	409.0	3,338.0	1,584.0	2,083.0
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	1,595.0	(2,739.0)	191.0	(1,033.0)	(1,589.0)	(475.0)
	d) Employee benefits expense	6,073.0	4,726.0	4,500.0	15,077.0	12,543.0	16,756.0
	e) Depreciation and amortisation expense	589.0	823.0	612.0	2,160.0	1,961.0	2,708.0
	f) Impairment / (Reversal)	(213.0)	152.0	-	(61.0)	-	73.0
	g) Finance Costs	21.0	23.0	14.0	60.0	40.0	42.0
	h) Other expenses	8,260.0	7,091.0	7,379.0	23,097.0	23,321.0	33,864.0
	Total expenses (4)	24,736.0	20,957.0	20,531.0	67,130.0	62,985.0	87,423.0
5.	Profit before exceptional items and tax (3-4)	7,853.0	10,494.0	6,486.0	27,007.0	19,876.0	25,337.0
6.	Less: Exceptional items	-	-	-	-	-	-
7.	Profit before tax (5-6)	7,853.0	10,494.0	6,486.0	27,007.0	19,876.0	25,337.0
8.	Tax expenses						
	Current Tax	2,271.0	3,006.0	1,722.0	7,468.0	5,269.0	6,502.0
	Deferred Tax	(337.0)	(192.0)	(59.0)	(426.0)	(109.0)	4.0
	Tax for earlier years	-	-	(293.0)	-	(421.0)	(421.0)
9.	Net Profit for the period/ year (7-8)	5,919.0	7,680.0	5,116.0	19,965.0	15,137.0	19,252.0
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains/(losses) on defined benefit plans	236.0	(564.0)	128.0	(305.0)	(230.0)	94.0
	ii. Income tax effect	(59.0)	142.0	(32.0)	77.0	58.0	(24.0)
	Total Other Comprehensive Income, net of tax	177.0	(422.0)	96.0	(228.0)	(172.0)	70.0
11.	Total Comprehensive Income for the period/year (9+10)	6,096.0	7,258.0	5,212.0	19,737.0	14,965.0	19,322.0
12.	Paid-up equity share capital (Face Value Rs 10/- each)	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0	1,660.0
13.	Other equity excluding Revaluation reserve as per Balance sheet	-	-	-	-	-	59,989.0
14.	Earnings per equity share (of Rs 10/- each) *(not annualised)						
	(a) Basic and Diluted (in Rs.)	* 35.7	* 46.3	* 30.8	* 120.3	* 91.2	116

Notes:

- The above results have been reviewed by Audit Committee and approved by the Board of Directors of the Company at meeting held on May 15, 2023 and have been subjected to a limited review by the Statutory Auditors of the Company.
- Results for all above period have been prepared in accordance with Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
- Previous period figures have been regrouped/ reclassified wherever necessary.

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited.

Milind Vasant
Thatte
Digitally signed by
Milind Vasant Thatte
Date: 2023.05.15
19:26:24 +05'30'
Milind Thatte
Managing Director

Place : Mumbai

Date : May 15, 2023

Please visit us at our website www.pghealthindia.com

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Health Limited** ("the Company") for the quarter ended March 31, 2023 and for the period from July 01, 2022 to March 31, 2023 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure

HARIBHAKTI & CO. LLP

Chartered Accountants

Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No. 103523W/W100048

**SUMANT
MANGESH
SAKHARDANDE**

Digitally signed by
SUMANT MANGESH
SAKHARDANDE
Date: 2023.05.15
20:00:48 +05'30'

Sumant Sakhardande

Partner

Membership No. : 034828

UDIN: 23034828BGWUEE9389

Place: Mumbai

Date: May 15, 2023